

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1. (Currently Amended) A method of inhibiting ~~A compound which inhibits the~~ a hedgehog pathway in a normal cell, comprising administering a therapeutically effective amount of a compound that inhibits the hedgehog pathway in a normal cell but and does not inhibit the hedgehog pathway in a patched-null cell.
2. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound has a molecular weight less than about 2000 amu.
3. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound has a molecular weight less than about 1000 amu.
4. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound causes a decrease in *gli* transcription of at least about 5% relative to an untreated control cell.
5. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound causes a decrease in *gli* transcription of at least about 10% relative to an untreated control cell.
6. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound causes a decrease in *gli* transcription of at least about 20% relative to an untreated control cell.
7. (Currently Amended) The method ~~compound~~ of claim 1, wherein the compound binds to *patched*.

8. (Currently Amended) The method compound of claim 1, wherein the compound inhibits the *hedgehog* pathway with an IC_{50} less than about 1 μ M.

9. (Currently Amended) The method compound of claim 1, wherein the compound inhibits the *hedgehog* pathway with an IC_{50} less than about 100 nM.

10. (Currently Amended) The method compound of claim 1, wherein the compound inhibits the *hedgehog* pathway with an IC_{50} less than about 10 nM.

AI 11. (Currently Amended) The method compound of claim 2, wherein the compound causes a decrease in *gli* transcription of at least about 5% relative to an untreated control cell.

12. (Currently Amended) The method compound of claim 2, wherein the compound causes a decrease in *gli* transcription of at least about 10% relative to an untreated control cell.

13. (Currently Amended) The method compound of claim 2, wherein the compound causes a decrease in *gli* transcription of at least about 20% relative to an untreated control cell.

14. (Currently Amended) The method compound of claim 2, wherein the compound binds to *patched*.

15. (Currently Amended) The method compound of claim 2, wherein the compound inhibits the *hedgehog* pathway with an IC_{50} less than about 1 μ M.

16. (Currently Amended) The method compound of claim 2, wherein the compound inhibits the *hedgehog* pathway with an IC_{50} less than about 100 nM.

17. (Currently Amended) The method compound of claim 2, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 10 nM.

18. (Currently Amended) The method compound of claim 4, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 1 μ M.

19. (Currently Amended) The method compound of claim 4, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 100 nM.

20. (Currently Amended) The method compound of claim 4, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 10 nM.

21. (Currently Amended) The method compound of claim 11, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 1 μ M.

22. (Currently Amended) The method compound of claim 11, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 100 nM.

23. (Currently Amended) The method compound of claim 11, wherein the compound inhibits the *hedgehog* pathway with an IC₅₀ less than about 10 nM.

24. (Currently Amended) The method compound of claim 2, wherein the compound increases PKA activity in a cell by a factor of at least about 2 relative to an untreated control cell.

25. (Currently Amended) The method compound of claim 2, wherein the compound increases PKA activity in a cell by a factor of at least about 3 relative to an untreated control cell.


26. (Currently Amended) The method compound of claim 2, wherein the compound increases PKA activity in a cell by a factor of at least about 5 relative to an untreated control cell.

27. (Currently Amended) The method compound of claim 8, wherein the compound increases PKA activity in a cell by a factor of at least about 2 relative to an untreated control cell.

A1 28. (Currently Amended) The method compound of claim 8, wherein the compound increases PKA activity in a cell by a factor of at least about 3 relative to an untreated control cell.

29. (Currently Amended) The method compound of claim 8, wherein the compound increases PKA activity in a cell by a factor of at least about 5 relative to an untreated control cell.

30. (Currently Amended) A method of inhibiting A compound which inhibits activation of the a hedgehog pathway by a hedgehog protein, comprising administering a therapeutically effective amount of a compound that inhibits the hedgehog pathway in a normal cell but ~~but~~ does not inhibit activation of the hedgehog pathway by the following compound:



A2 31. (New) The method of claim 1, wherein inhibiting the *hedgehog* pathway inhibits angiogenesis.

32. (New) The method of claim 2, wherein inhibiting the *hedgehog* pathway inhibits angiogenesis.

33. (New) The method of claim 4, wherein inhibiting the *hedgehog* pathway inhibits angiogenesis.

34. (New) The method of claim 8, wherein inhibiting the *hedgehog* pathway inhibits angiogenesis.

35. (New) The method of claim 11, wherein inhibiting the *hedgehog* pathway inhibits angiogenesis.

A2

36. (New) The method of claim 1, wherein inhibiting the *hedgehog* pathway controls hair growth.

37. (New) The method of claim 2, wherein inhibiting the *hedgehog* pathway controls hair growth.

38. (New) The method of claim 4, wherein inhibiting the *hedgehog* pathway controls hair growth.

39. (New) The method of claim 8, wherein inhibiting the *hedgehog* pathway controls hair growth.

40. (New) The method of claim 11, wherein inhibiting the *hedgehog* pathway controls hair growth.

41. (New) A method of inhibiting angiogenesis, comprising administering to a patient a therapeutically effective amount of a compound that inhibits the hedgehog pathway in a normal cell but does not inhibit the *hedgehog* pathway in a *patched*-null cell.

A² 42. (New) A method of inhibiting controlling hair growth, comprising administering to a patient a therapeutically effective amount of a compound that inhibits the hedgehog pathway in a normal cell but does not inhibit the *hedgehog* pathway in a *patched*-null cell.

43. (New) A method of inhibiting the *hedgehog* pathway in a cell having a hedgehog gain-of-function phenotype, comprising administering a therapeutically effective amount of a compound that inhibits the hedgehog pathway in a normal cell but does not inhibit the *hedgehog* pathway in a *patched*-null cell.
